Other · developed by Heron Therapeutics
Granisetron extended release (GERSC) is a subcutaneously administered polymeric formulation of granisetron designed to release the drug slowly and continuously. It is studied for the prevention of acute and delayed chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic chemotherapy.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04085393 | Phase 2 | Chemotherapy-induced Nausea and Vomiting | Withdrawn | HRTX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Chemotherapy-induced Nausea and Vomiting
Updated Oct 18, 2026. Something wrong or missing? Report it on the HRTX page.
See HRTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
HRTX catalysts and pipeline →